Manzke, Jana and Stauf, Raphael and Neumann, Bernd and Molitor, Ernst and Hischebeth, Gunnar and Simon, Michaela and Jantsch, Jonathan and Roedel, Juergen and Becker, Soeren L. and Halfmann, Alexander and Wichelhaus, Thomas A. and Hogardt, Michael and Serr, Annerose and Hess, Christina and Wendel, Andreas F. and Siegel, Ekkehard and Rohde, Holger and Zimmermann, Stefan and Steinmann, Joerg (2022) German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant Pseudomonas aeruginosa Isolates Using a Commercially Available Broth Microdilution Assay. ANTIBIOTICS-BASEL, 11 (5): 545. ISSN 2079-6382,
Full text not available from this repository. (Request a copy)Abstract
Multidrug resistance is an emerging healthcare issue, especially concerning Pseudomonas aeruginosa. In this multicenter study, P. aeruginosa isolates with resistance against meropenem detected by routine methods were collected and tested for carbapenemase production and susceptibility against ceftazidime-avibactam. Meropenem-resistant isolates of P. aeruginosa from various clinical materials were collected at 11 tertiary care hospitals in Germany from 2017-2019. Minimum inhibitory concentrations (MICs) were determined via microdilution plates (MICRONAUT-S) of ceftazidime-avibactam and meropenem at each center. Detection of the presence of carbapenemases was performed by PCR or immunochromatography. For meropenem-resistant isolates (n = 448), the MIC range of ceftazidime-avibactam was 0.25-128 mg/L, MIC90 was 128 mg/L and MIC50 was 16 mg/L. According to EUCAST clinical breakpoints, 213 of all meropenem-resistant P. aeruginosa isolates were categorized as susceptible (47.5%) to ceftazidime-avibactam. Metallo-beta-lactamases (MBL) could be detected in 122 isolates (27.3%). The MIC range of ceftazidime-avibactam in MBL-positive isolates was 4-128 mg/L, MIC90 was >128 mg/L and MIC50 was 32 mg/L. There was strong variation in the prevalence of MBL-positive isolates among centers. Our in vitro results support ceftazidime-avibactam as a treatment option against infections caused by meropenem-resistant, MBL-negative P. aeruginosa.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ; ceftazidime-avibactam; susceptibility testing; carbapenemases |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 29 Feb 2024 16:07 |
| Last Modified: | 29 Feb 2024 16:07 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58632 |
Actions (login required)
 |
View Item |
